Comparative Pharmacology
Head-to-head clinical analysis: PITOCIN versus SYNTOCINON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PITOCIN versus SYNTOCINON.
PITOCIN vs SYNTOCINON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Oxytocin receptor agonist; stimulates uterine smooth muscle contractions and myoepithelial cell contraction in the mammary gland.
Synthetic oxytocin binds to oxytocin receptors in the myometrium, causing increased intracellular calcium and uterine smooth muscle contraction. Also acts on mammary gland myoepithelium for milk ejection.
IV infusion: 0.5-2 mU/min, increase by 1-2 mU/min every 15-60 minutes until contractions are established; maximum 20 mU/min.
10 units (1 mL) intravenously as a single dose after delivery; continuous infusion: 20 units in 1 L of normal saline or lactated Ringer's solution at 2-10 mU/min (0.1-0.5 mL/min) titrated to uterine response.
None Documented
None Documented
Terminal elimination half-life is 3-5 minutes (plasma) with a terminal half-life of 1-6 minutes for exogenously administered oxytocin; clinical effects persist 20-30 minutes due to receptor binding.
Terminal elimination half-life: 1–6 minutes (intravenous); 1–9 minutes (intramuscular). Clinically, effects dissipate rapidly after infusion cessation.
Primarily renal: 90-95% of the dose is excreted in urine as intact peptide and metabolites; <1% excreted in feces via bile.
Renal: >99% as intact oxytocin; biliary/fecal: negligible (<1%).
Category C
Category C
Oxytocic
Oxytocic